history
NeuroTherapia, Inc, a Delaware C-corporation was founded in 2015 by the Cleveland Clinic and two of its physician scientists. The Company is developing new drugs to treat diseases related to neuroinflammation with an initial focus on Alzheimer’s disease (AD) therapies. The Company’s lead molecule, NTRX-07, is a cannabinoid type II receptor agonist.
Extensive research demonstrated the ability of NTRX-07 to reduce neuroinflammation and improve neuronal function, leading to improvements in learning and memory, without any of the psychoactive side effects associated with cannabinoids. The Company completed initial preclinical toxicology work in 2018, and recruited Tony Giordano, Ph.D., an experienced biotechnology CEO to run NeuroTherapia. The Company has completed Phase I clinical development, demonstrating the safety of NTRX-07 at doses expected to be efficacious based on animal modeling, and will begin Phase 2a studies in 2024 with testing in AD patients.